Results 31 to 40 of about 34,080 (270)
Systematic identification of non-coding pharmacogenomic landscape in cancer
In this study the authors build lncRNA-drug response models for 265 anti-cancer agents across 27 cancer types. They report their cancer cell line based lncRNA EN-models are able to effectively predict therapeutic outcome for breast cancer, ovarian cancer,
Yue Wang +6 more
doaj +1 more source
COMPARISON OF CLINICAL PHARMACOGENETIC RECOMMENDATIONS ACROSS THERAPEUTIC AREAS
OBJECTIVES: Evaluations from pharmacogenetics implementation programs at major U.S. medical centers have reported variability in the clinical adoption of pharmacogenetics across therapeutic areas.
Luzum, Jasmine A. +2 more
core +1 more source
Integrating rare genetic variants into pharmacogenetic drug response predictions
Background Variability in genes implicated in drug pharmacokinetics or drug response can modulate treatment efficacy or predispose to adverse drug reactions.
Magnus Ingelman-Sundberg +3 more
doaj +1 more source
Pharmacogenetics of OPRM1 [PDF]
Pharmacogenetic research has the potential to explain the variation in treatment efficacy within patient populations. Understanding the interaction between genetic variation and medications may provide a method for matching patients to the most effective therapeutic options and improving overall patient outcomes.
Richard C, Crist, Wade H, Berrettini
openaire +2 more sources
Warfarin pharmacogenetics [PDF]
The cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotypes have been strongly and consistently associated with warfarin dose requirements, and dosing algorithms incorporating genetic and clinical information have been shown to be predictive of stable warfarin dose.
Julie A, Johnson, Larisa H, Cavallari
openaire +2 more sources
miRNAs as Key Players in the Management of Cutaneous Melanoma
The number of treatment options for melanoma patients has grown in the past few years, leading to considerable improvements in both overall and progression-free survival.
Celeste Lorusso +4 more
doaj +1 more source
Objective Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus (SLE), but the weight‐based dosing does not account for clinical factors that can introduce individual variability in drug metabolism and clearance. We leveraged longitudinal data from a prospective SLE cohort to identify clinical factors that predict ...
Jay J. Patel +6 more
wiley +1 more source
Background Pharmacogenetics (PGx) is currently implemented in hospitals to optimize therapy with high-risk drugs. However, many drugs with dosing recommendations from the Dutch Pharmacogenetics Working Group and the Clinical Pharmacogenetics ...
P. C. D. Bank +2 more
doaj +1 more source
This study presents a single‐cell atlas of pseudomyxoma peritonei spanning primary and paired metastatic lesions. Distinct epithelial substates, stromal remodeling, immune exclusion, lipid metabolic reprogramming, and a candidate angiogenic network were identified in metastatic lesions.
Xi Li +14 more
wiley +1 more source
Palatable food alleviates stress and prevents anxiety. This study uncovers a dedicated neural pathway: dopamine release in the PFC activates D1R neurons, whose projections to the peri‐PVN engage a population of anxiolytic CRFR1 neurons. These neurons then inhibit stress‐induced hyperactivity of PVNCRF neurons, providing a circuit‐level explanation for ...
Yuchuan Hong +12 more
wiley +1 more source

